Eyeing a potential drug launch early next year, Apnimed Inc. has entered the public market via an upsized IPO, pricing 12 million shares at $16 apiece for gross proceeds of $192 million. Another $24 million could come if underwriters exercise their overallotment option for an additional 1.5 million shares.
Total med-tech financing through the first half (H1) of 2026 reached $12.66 billion, down from 2025’s $17.56 billion but in line with 2024’s $13.94 billion over the same period.
New drug approvals, financings and deals were seen across the Asia-Pacific biotech sector this week, with China’s National Medical Products Administration (NMPA) granting clearances to Takeda Pharmaceutical Co. Ltd.’s oral orexin receptor 2 agonist oveporexton for narcolepsy, as well as Haisco Pharmaceutical Group’s ciprocopan (HSK-39297) for paroxysmal nocturnal hemoglobinuria.
